SEARCH
Search Details
OKAMURA YasuyoshiGraduate School of Medicine / Faculty of Medical SciencesAssistant Professor
Research activity information
■ Paper- Elsevier BV, Jan. 2025, Urologic Oncology: Seminars and Original Investigations, 43(1) (1), 63.e19 - 63.e27Scientific journal
- Elsevier BV, Dec. 2024, Clinical Genitourinary Cancer, 22(6) (6), 102236 - 102236Scientific journal
- Elsevier BV, Nov. 2024, Urologic Oncology: Seminars and Original InvestigationsScientific journal
- Springer Science and Business Media LLC, Oct. 2024, International Journal of Clinical Oncology, 29(12) (12), 1931 - 1936Scientific journal
- ABSTRACT Background This study aimed to investigate the perioperative outcomes of robot‐assisted laparoscopic pyeloplasty (RLP) using the recently launched hinotori surgical robot system. Methods This retrospective study compared the perioperative outcomes of 11 consecutive patients who underwent RLP with the hinotori surgical robot system from October 2022 to March 2024 (hinotori group) and 30 consecutive patients who underwent RLP with the da Vinci system from March 2019 to September 2022 (da Vinci group). Results The patient characteristics of the groups were similar. The median operative times in the hinotori and da Vinci groups were 236.0 and 231.5 min, respectively (p = 0.480). The success rates were 100.0% and 96.7%, respectively (p = 1.000). Clavien‐Dindo grade ≥ 3 complications occurred in one patient (9.1%) in the hinotori group and one patient (3.3%) in the da Vinci group (p = 0.470). Conclusions The perioperative outcomes in the hinotori group were not inferior to those in the da Vinci group.Wiley, Sep. 2024, The International Journal of Medical Robotics and Computer Assisted Surgery, 20(5) (5)Scientific journal
- Springer Science and Business Media LLC, Sep. 2024, Journal of Bone and Mineral Metabolism, 42(6) (6), 668 - 674Scientific journal
- INTRODUCTION: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC). METHODS: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared. RESULTS: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups. CONCLUSIONS: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.May 2024, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 18(5) (5), E162-E166, English, International magazineScientific journal
- The present study aimed to clarify the relationship between the therapeutic outcome of combination regimens, including immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs), and cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). The present study retrospectively assessed the association between treatment efficacy and prognosis with or without CN, and the timing of CN in 151 patients treated with combination regimens for mRCC who were categorized as intermediate/poor risk. The first-line regimens included the ICI-ICI and ICI-TKI regimens in 98 and 53 cases, respectively. In patients with recurrence after radical surgery (n=66), the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 33.6 months and not reached (NR) (P=0.4032), respectively, and the 50% OS times were 53.7 months and NR (P=0.6886), respectively. Among the 38 patients with metastasis from the initial diagnosis who underwent upfront CN, the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 10.5 and 8.2 months (P=0.5806), respectively, and the 50% OS times were NR and 15.8 months (P=0.0587), respectively. Among the 51 patients who did not receive upfront CN, the 50% PFS time of the ICI-TKI group was significantly higher than that in the ICI-ICI group (4.1 months and NR, respectively; P=0.0210), and the 50% OS times were 29.8 months and NR (P=0.7343), respectively. In conclusion, according to the analysis of real-world data, good therapeutic efficacy can be achieved with any regimen in patients with recurrence after radical surgery. In addition, improved results could be achieved through treatment with ICI-TKI in patients without upfront CN.Nov. 2023, Oncology letters, 26(5) (5), 470 - 470, English, International magazineScientific journal
- INTRODUCTION: The performance of robot-assisted laparoscopic pyeloplasty has recently been increasing in frequency. However, patients with duplicated renal pelvises and ureters can present challenges. CASE PRESENTATION: A 71-year-old woman presented with flank pain and was diagnosed with ureteropelvic junction obstruction with an incomplete duplicated collecting system. Preoperative imaging did not reveal the details of the stenosis. Therefore, three reconstructive procedures were prepared: The Anderson-Hynes procedure, end-to-side pyeloureterostomy, and upper pole ureter to lower pole pyeloplasty with the Anderson-Hynes procedure for the lower pole. These procedures were determined by the length of the intact ureter and the presence of crossed vessels. During the surgery, the crossing vein was severed, allowing successful reconstruction with Anderson-Hynes anastomosis. CONCLUSION: Preoperative evaluation and preparation of multiple surgical techniques are crucial in robot-assisted laparoscopic pyeloplasty for incomplete duplicated collecting systems.Nov. 2023, IJU case reports, 6(6) (6), 357 - 361, English, International magazine
- Oct. 2023, Clinical genitourinary cancer, 21(5) (5), 613.e1-613.e6, English, International magazine
- OBJECTIVES: The efficacy of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs) has been suggested in the real-world setting. We retrospectively examined the efficacy of CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC. METHODS: Synchronous mRCC patients who received nivolumab plus ipilimumab at Kobe University Hospital or five affiliated hospitals between October 2018 and December 2021 were included in this study. We compared the outcomes of objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) between patients with CN prior to systemic therapy and without CN. In addition, patients were 1:1 matched by propensity scores accounting for factors associated with treatment assignment. RESULTS: Twenty-one patients received CN prior to nivolumab plus ipilimumab (Prior CN) and 33 received nivolumab plus ipilimumab alone (Without CN). PFS of the Prior CN group was 10.8 months (95%CI 5.5-NR) and 3.4 months (95%CI 2.0-5.9) for the Without CN group (p = 0.0158). OS of Prior CN was 38.4 months (95%CI NR-NR) and 12.6 months (95%CI 4.2-30.8) for Without CN (p = 0.0024). Univariate and multivariate analyses identified prior CN as a significant prognostic indicator for PFS and OS. Moreover, propensity score matching analysis showed significant improvements in PFS and OS in Prior CN. CONCLUSIONS: Patients who underwent CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC had a better prognosis than patients treated with nivolumab plus ipilimumab alone. These results suggest the efficacy of prior CN for synchronous mRCC with ICI combination therapy.Sep. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(9) (9), 746 - 752, English, International magazineScientific journal
- BACKGROUND: The objective of this study was to evaluate the background and treatment course of patients with metastatic prostate cancer (PC), with a particular focus on radiographic progression in the absence of prostate-specific antigen (PSA) progression. METHODS: The study population consisted of 229 patients with metastatic hormone-sensitive PC (HSPC), who received prostate biopsy and androgen deprivation therapy at Kobe University Hospital between January 2008 and June 2022. Clinical characteristics were retrospectively evaluated using medical records. PSA progression-free status was defined as ≤1.05 times greater than that from 3 months before. Multivariate analyses were performed using the Cox proportional hazards regression model to identify parameters associated with time to progression on imaging without PSA elevation. RESULTS: A total of 227 patients with metastatic HSPC without neuroendocrine PC were identified. The median follow-up period was 38.0 months, with a median overall survival of 94.9 months. Six patients exhibited disease progression on imaging without PSA elevation during HSPC treatment, three during first-line castration-resistant PC (CRPC) treatment, and two during late-line CRPC treatment. The rate of disease progression without PSA elevation at 3 years after treatment initiation was 7.4%. Multivariate analysis revealed that organ metastases and upfront treatment with docetaxel or androgen receptor axis-targeted therapy were independent prognostic factors for imaging progression without PSA elevation. CONCLUSIONS: Disease progression on imaging without PSA elevation occurred not only during HSPC treatment and first-line CRPC treatment, but also during late-line CRPC treatment. Patients with visceral metastases or those treated with upfront androgen receptor axis-targeted or docetaxel may be more prone to such progression.Sep. 2023, The Prostate, 83(13) (13), 1270 - 1278, English, International magazineScientific journal
- OBJECTIVES: We investigated poor prognosticators in advanced or unresectable urothelial carcinoma, focusing on renal parenchymal invasion (RPI). METHODS: This study included 48 bladder cancer (BC) and 67 upper tract urothelial carcinoma (UTUC) patients treated with pembrolizumab from December 2017 to September 2022 at Kobe University Hospital. Medical records were retrospectively reviewed for clinical characteristics, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Multivariate analyses were performed using the Cox proportional hazard regression model to identify parameters associated with either PFS or OS. RESULTS: Of 67 UTUC patients, 23 had RPI and 41 patients did not, while 3 cases could not be evaluated. Patients with RPI were predominantly elderly and had liver metastases. ORR for patients with RPI was 8.7%, while it was 19.5% for those without RPI. PFS was significantly shorter for patients with RPI compared with those without RPI. Patients with RPI had significantly shorter OS than those without RPI. On multivariate analysis, performance status (PS) ≥ 2, neutrophil-lymphocyte ratio (NLR) ≥ 3, C-reactive protein ≥0.3 mg/dL and RPI were independent prognostic factors for PFS. PS ≥ 2, NLR ≥ 3, visceral metastasis and RPI were independent prognostic factors for OS. UTUC patient OS was significantly shorter than BC patient OS, while no significant difference in PFS or OS was observed between BC patients and UTUC patients without RPI. CONCLUSIONS: RPI was a poor prognostic factor in advanced urothelial carcinoma treated with pembrolizumab, possibly resulting in a poorer prognosis for UTUC compared with BC.Sep. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(9) (9), 779 - 786, English, International magazineScientific journal
- Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60-70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 antibodies compared to the mice treated by the antibodies alone. This result suggests that B. longum 420 oral cancer vaccine as an adjunct to ICIs could provide a novel treatment option for RCC patients. Our microbiome analysis revealed that the proportion of Lactobacilli was significantly increased by B. longum 420. Although the detailed mechanism of action is unknown, it is possible that microbiome alteration by B. longum 420 enhances the efficacy of the ICIs.Jun. 2023, Scientific reports, 13(1) (1), 9994 - 9994, English, International magazineScientific journal
- OBJECTIVE: This study retrospectively reviewed the clinical characteristics and treatment outcomes of patients with histologically diagnosed treatment-related pure small-cell neuroendocrine prostate cancer. METHODS: We retrospectively evaluated data for 13 patients with treatment-related neuroendocrine prostate cancer who were diagnosed between May 2015 and February 2022. Standardized systemic therapies of etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan were selected as sequential treatments. Cancer-specific survival and progression-free survival were evaluated as the primary endpoint. The Cox proportional hazards model was used to evaluate the relationships between treatment regimens, clinical variables, cancer-specific survival and progression-free survival. RESULTS: The median cancer-specific survival after diagnosis for all patients was 22.4 months (range 1.3-33.4 months). The median progression-free survival was 9.3 months after first-line etoposide plus cisplatin (or carboplatin) treatment (n = 13); 4.2 months after second-line amrubicin treatment (n = 4); and >15 months after third-line nogitecan treatment (n = 2). The median progression-free survival after first-line chemotherapy of the liver metastasis (-) group was 10.2 months, and that of the (+) group was 5.3 months (P = 0.015, hazard ratio = 11.6, 95% confidence interval = 1.01 - 133.7). No clinicopathological parameters were identified as significant independent predictors of cancer-specific survival in univariate analysis. CONCLUSION: Sequential chemotherapy with etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan may be helpful for patients with treatment-related pure small-cell neuroendocrine prostate cancer. Early biopsy of metastases and initiation of effective therapy is essential for patients with progressive castration-resistant prostate cancer and low prostate-specific antigen.Jun. 2023, Japanese journal of clinical oncology, 53(6) (6), 522 - 529, English, International magazineScientific journal
- PURPOSE: Non-absorbable clips are widely used in urologic surgery and they may come in contact with an open urinary tract intraoperatively. As a result, stray clips in the urinary tract and associated intractable infections have been reported. We developed a bioabsorbable metal and evaluated whether it would dissolve if it strayed into the urinary tract. METHODS: We prepared four types of alloys mainly comprising zinc (Zn) with small amounts of magnesium (Mg) and strontium (Sr), and the biological effects, degradability, strength, and ductility were investigated. Each alloy was implanted in the bladder of five rats for 4, 8, and 12 weeks. The alloys were removed and evaluated for degradability, stone adhesion, and tissue changes. The Zn-Mg-Sr alloy had degradability and no stone adhesion in the rat experiments, and it was implanted in the bladders of five pigs for 24 weeks. The Mg and Zn levels in the blood were measured, and staple changes were confirmed by cystoscopy. RESULTS: Zn-Mg-Sr alloys showed the best degradability of 6.51% at 12 weeks. In pig experiments, the degradation rate was 3.72% at 24 weeks. None of the pigs had changes in the Zn or Mg concentrations in the blood. Overall, the bladder incision was healed and the gross pathology showed wound healing. CONCLUSIONS: The Zn-Mg-Sr alloys were safely used in animal experiments. Furthermore, the alloys are easy to process and can be formed into various shapes, such as staples, making them useful in robotic surgery.Apr. 2023, World journal of urology, 41(4) (4), 1181 - 1186, English, International magazineScientific journal
- Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.2023, Urologia internationalis, 107(3) (3), 321 - 326, English, International magazineScientific journal
- 泌尿器科紀要刊行会, Dec. 2022, 泌尿器科紀要, 68(12) (12), 399 - 400, Japanese後腹膜腫瘍摘除術を施行し診断したSolitary fibrous tumorの1例
- PURPOSE: Two methods are used to identify sarcopenia by calculating skeletal muscle area on computed tomography: the skeletal muscle index (SMI) and the psoas muscle index (PMI). Programmed death (PD)-1 inhibitors are helpful in treating metastatic renal cell carcinoma (mRCC). However, there remains insufficient information regarding a clear and easy-to-use biomarker for predicting the response to PD-1 inhibitors in patients with mRCC. Therefore, we investigated the influence of sarcopenia on clinical outcomes in patients with mRCC undergoing treatment with nivolumab. MATERIALS AND METHODS: This study evaluated 96 patients with RCC who received nivolumab. The SMI and PMI were calculated for each patient and normalized for stature by use of the following formulas: SMI (cm²/m²)=([skeletal muscle cross-sectional area at the level of L3]/[height]²) and PMI (cm²/m²) = ([left-right sum of the psoas muscle areas at the level of L3]/[height]²). The relationship of the clinical variables with progression-free survival and overall survival (OS) was examined using a Cox proportional hazards model. RESULTS: According to the SMI-based definition of sarcopenia, 74.0% of patients had sarcopenia. However, according to the PMI-based definition of sarcopenia, only 34.3% of patients were diagnosed with sarcopenia. Multivariate analysis identified sarcopenia based on PMI (hazard ratio [HR], 3.85; 95% confidence interval [CI], 2.04-7.26; p<0.001) and International Metastatic RCC Database Consortium poor risk status (HR, 1.90; 95% CI, 1.03-3.50; p=0.041) as significant and independent prognostic factors of OS. CONCLUSIONS: PMI-based sarcopenia is a significant prognostic factor for OS in patients with RCC who receive nivolumab therapy.Jul. 2022, Investigative and clinical urology, 63(4) (4), 415 - 424, English, International magazineScientific journal
- OBJECTIVE: In renal cell carcinoma with inferior vena cava (IVC) thrombus, adhesion to, or invasion into, the IVC wall will often increase the level of surgical difficulty and even necessitate resection of the IVC. It will generally be difficult to perform an accurate preoperative assessment using the standard imaging modalities of contrast-enhanced computed tomography and standard magnetic resonance imaging (MRI). Cine MRI is an MRI sequence that captures motion to produce detailed information on both the anatomy and the dynamic motion. In the present study, we evaluated the accuracy of preoperative cine MRI for determining the need for IVC wall resection, with validation of the imaging findings according to the intraoperative findings. METHODS: A total of 15 patients who had undergone radical nephrectomy and tumor thrombectomy from May 2018 to April 2020 met the inclusion criteria. The primary outcome of interest was the need for IVC resection because of adhesion or invasion of a venous tumor thrombus. Cine MRI was used to evaluate the blood flow between the tumor thrombus and the IVC wall and the presence of tumor thrombus mobility during free respiration. The sensitivity and specificity were calculated for preoperative cine MRI for determining the need for IVC wall resection. The Fisher exact test was used to determine the association between intraoperative IVC wall resection and the cine MRI findings. Furthermore, receiver operating characteristic curves and the area under the curve were used to compare the accuracy of conventional MRI and cine MRI. RESULTS: Of the 15 patients, 8 (53.3%) had undergone IVC resection. We found that the absence of both dynamic blood flow and tumor thrombus mobility on cine MRI could reliably predict for IVC resection with 100% (95% confidence interval, 51.8%-100%) sensitivity and 85.7% (95% confidence interval, 42.1%-1.00%) specificity. The area under the receiver operating characteristic curve was 0.821 for conventional MRI and 0.929 for cine MRI. CONCLUSIONS: In the preoperative setting, cine MRI could be a helpful examination modality to predict for the need for IVC wall resection for patients with renal cell carcinoma with venous tumor thrombus.Mar. 2022, Journal of vascular surgery. Venous and lymphatic disorders, 10(4) (4), 908 - 915, English, International magazineScientific journal
- BACKGROUND/AIM: The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively. PATIENTS AND METHODS: We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups. RESULTS: Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04). CONCLUSION: Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.Feb. 2022, Anticancer research, 42(2) (2), 973 - 979, English, International magazineScientific journal
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, OP79 - 07, Japanese下大静脈塞栓を有する腎癌症例に対する術前アベルマブ、アキシチニブ併用療法の有用性に関する検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP02 - 09, Japaneseニボルマブを使用した腎細胞癌患者の予後と骨格筋量との関連についての検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP03 - 04, Japanese当院における進行性腎癌に対するカボザンチニブの初期投与経験
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP03 - 10, Japanese神戸大学における転移性腎癌に対するアキシチニブrechallengeの治療成績
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP04 - 04, Japanese神戸大学における転移性腎細胞癌に対するイピリムマブ・ニボルマブ併用療法の治療成績
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP22 - 07, Japanese生体分解性亜鉛マグネシウム合金の開発及び、尿路手術での使用の検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP26 - 02, Japaneseペムブロリズマブを使用した進行性尿路上皮癌患者の予後予測因子についての免疫組織学的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP36 - 01, Japaneseホルモン治療に伴う前立腺癌者の骨密度および骨代謝マーカーの推移についての前向き観察研究
- (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP55 - 06, Japanese転移性腎癌における単発転移に対するmetastasectomyの有用性の臨床的検討
- (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 166 - 166, English術前cine MRIによる腎癌血栓の下大静脈壁への癒着評価の有効性(The efficacy of pre-operative cine MRI to evaluate the adhesion of renal cancer thrombus to the wall of inferior vena cava)
- (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 199 - 199, Japanese転移性腎細胞癌に対するイピリムマブ・ニボルマブ併用療法における初回投与時期の検討
- (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, O22 - 5, English進行性尿路上皮癌に対するPembrolizumab投与後のPaclitaxel/Carboplatin療法の成績
- (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, O23 - 3, English神戸大学における転移性腎癌に対するアキシチニブrechallengeの治療成績
- (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, P27 - 1, English非淡明型腎細胞癌に対するニボルマブ・イピリムマブ併用療法の成績
- (一社)日本癌治療学会, Oct. 2021, 日本癌治療学会学術集会抄録集, 59回, P29 - 6, English去勢抵抗性前立腺癌に対するカバジタキセルの治療効果と安全性の検討
- Wiley, Jul. 2021, International Journal of UrologyScientific journal
- 泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 252 - 252, Japanese腎癌単発転移に対するMetastasec-tomyの有用性の臨床的検討
- 泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 253 - 253, JapanesePresurgical therapyによって腎静脈内まで腫瘍塞栓が縮小し腹腔鏡下に摘除し得た腎癌下大静脈腫瘍塞栓の1例
- 泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 256 - 256, Japanese進行性尿路上皮癌に対するPembrolizumab治療における好中球/リンパ球比の意義
- 泌尿器科紀要刊行会, Jun. 2021, 泌尿器科紀要, 67(6) (6), 265 - 265, Japanese前立腺小細胞癌に対する2nd line化学療法としてのアムルビシンの使用経験
- BACKGROUND: Although bone metastasis beyond the vertebrae and pelvis has been a key factor in prognostic models of metastatic hormone-sensitive prostate cancer (mHSPC), the clinical significance of it is still unclear. The present study evaluated the prognostic impact of the volume of bone metastasis beyond the vertebrae and pelvis on the outcomes of mHSPC and created an ideal risk classification based on it. METHODS: We retrospectively reviewed 197 patients with mHSPC who were treated with combined androgen blockade as the initial treatment between June 2003 and October 2019. We calculated the bone scan index (BSI), including the BSI beyond the vertebrae and pelvis (bBSI), using BONENAVI, and investigated the association between the BSI and the overall survival (OS) of mHSPC. RESULTS: According to the CHAARTED criteria, 91 and 106 patients were classified into the low- and high-volume groups, respectively. Of the 79 patients who did not have visceral metastasis in the high-volume group, those with a bBSI ≤ 0.27 (n = 16) showed a favorable OS, as did those in the low-volume group. The modified CHAARTED high-volume group (presence of visceral metastases or 4 bone lesions with a bBSI > 0.27) showed a significantly shorter OS than others, with a hazard ratio (HR) of 4.69 (p < 0.001), which was higher than that observed with the original CHAARTED criteria (HR = 4.33). CONCLUSIONS: Our data suggested that considering the volume of bone metastasis beyond the vertebrae and pelvis may help to improve the accuracy of risk classification. Further large-scale prospective studies are needed to validate our findings.May 2021, International journal of clinical oncology, 26(8) (8), 1533 - 1540, English, Domestic magazineScientific journal
- PURPOSE: Metallic medical devices are typically constructed from non-bioabsorbable metals that remains in the body and causes considerable complications. Particularly in the urinary tract, calculus, intractable infection, and misdiagnosis as calculus are often caused by non-bioabsorbable metals. Here, we developed a zinc-magnesium alloy as a new bioabsorbable metal and sought to evaluate the bioabsorbable behavior of zinc and zinc-magnesium alloy in a rat bladder implantation model. METHODS: We prepared zinc-magnesium alloy wires with various proportions of magnesium and investigated the strength, shape retention, formability, and absorbability of these novel materials. Then, we implanted zinc and zinc-magnesium alloy rings formed by the wires into rat bladder. Rats were euthanized at the end of the observation period, and the rings were removed for volume evaluation. Extracted bladder tissues were subjected to histological analysis. RESULTS: The strength of the zinc wire was enhanced by more than fourfold upon the addition of magnesium, without loss of ductility. Linear reduction of ring volume in urine was observed based on the concentration of magnesium within the ring. Nearly all rings were covered with a thin layer of calculus. Histological findings of the transected urinary bladder tissues did not differ among groups. CONCLUSIONS: Zinc-magnesium alloy is a promising candidate for use as a bioabsorbable medical device in the urinary tract.Jan. 2021, World journal of urology, 39(1) (1), 201 - 208, English, International magazineScientific journal
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1149 - 1149, Japanese当院における非転移性去勢抵抗性前立腺癌に対する治療成績の検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1193 - 1193, Japanese進行性腎細胞癌患者におけるニボルマブ関連続発性副腎不全の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1320 - 1320, Japanese神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌12例の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1594 - 1594, Japanese神戸大学における転移性腎癌に対するイピリムマブ・ニボルマブ併用療法の初期経験
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1707 - 1707, Japanese初診時にリンパ節転移を認めた上部尿路癌に対する集学的治療の検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1718 - 1718, Japanese当院における精巣腫瘍の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1745 - 1745, Japanese当科におけるクッシング症候群に対する腹腔鏡下副腎摘除術の手術成績と治療アウトカムに関する検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1798 - 1798, Japanese血清中可溶性PD-L1蛋白高値の根治切除不能または転移性の腎細胞癌におけるニボルマブの治療効果予測効果についての研究
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1843 - 1843, Japanese尿路上皮癌に対するPembrolizumabの治療効果についての検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1149 - 1149, Japanese当院における非転移性去勢抵抗性前立腺癌に対する治療成績の検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1193 - 1193, Japanese進行性腎細胞癌患者におけるニボルマブ関連続発性副腎不全の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1320 - 1320, Japanese神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌12例の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1594 - 1594, Japanese神戸大学における転移性腎癌に対するイピリムマブ・ニボルマブ併用療法の初期経験
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1707 - 1707, Japanese初診時にリンパ節転移を認めた上部尿路癌に対する集学的治療の検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1718 - 1718, Japanese当院における精巣腫瘍の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1745 - 1745, Japanese当科におけるクッシング症候群に対する腹腔鏡下副腎摘除術の手術成績と治療アウトカムに関する検討
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1798 - 1798, Japanese血清中可溶性PD-L1蛋白高値の根治切除不能または転移性の腎細胞癌におけるニボルマブの治療効果予測効果についての研究
- (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 1843 - 1843, Japanese尿路上皮癌に対するPembrolizumabの治療効果についての検討
- (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 322, Japanese当院におけるロボット支援根治的膀胱全摘除術の成績
- (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 358, Japanese非転移性去勢抵抗性前立腺癌に対するエンザルタミドとアビラテロンの治療効果
- (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 305, Japaneseニボルマブ治療後の転移性腎細胞癌における分子標的薬の治療成績
- 西日本泌尿器科学会, Oct. 2020, 西日本泌尿器科, 82(増刊) (増刊), 164 - 164, Japanese
- (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 305, Japaneseニボルマブ治療後の転移性腎細胞癌における分子標的薬の治療成績
- (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 322, Japanese当院におけるロボット支援根治的膀胱全摘除術の成績
- (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, P - 358, Japanese非転移性去勢抵抗性前立腺癌に対するエンザルタミドとアビラテロンの治療効果
- (一社)日本内分泌外科学会, Aug. 2020, 日本内分泌外科学会雑誌, 37(Suppl.1) (Suppl.1), S111 - S111, Japanese副腎皮質癌11例の臨床的検討
- (一社)腎癌研究会, 2020, 腎癌研究会会報, (50) (50), 16 - 16, Japanese下大静脈塞栓を有する腎癌患者に対する術前分子標的治療薬投与の有用性に関する検討
- UNLABELLED: Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis. MATERIALS AND METHODS: We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital. RESULTS: Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%). CONCLUSION: Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis.Nov. 2019, In vivo (Athens, Greece), 33(6) (6), 2013 - 2019, English, International magazine[Refereed]Scientific journal
- 西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 151 - 151, Japanese
- 西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 173 - 173, Japanese
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P35 - 7, English転移性腎癌におけるニボルマブ関連副腎不全の臨床的検討
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P36 - 4, English当院における進行性腎細胞癌に対するニボルマブの治療成績
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P40 - 2, English転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P40 - 6, English進行性腎細胞癌に対する一次治療におけるパゾパニブの有効性と安全性
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P41 - 1, English当院でのアラグリオを使用したTURBTの検討
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P41 - 7, English腎癌下大静脈腫瘍塞栓に対して術前分子標的薬投与を行った際の手術成績の比較検討
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P94 - 2, Englishロボット支援根治的前立腺全摘除術における拡大リンパ節郭清の検討
- (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, P103 - 7, English神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌10例の臨床的検討
- (一社)腎癌研究会, Jul. 2019, 腎癌研究会会報, (49) (49), 38 - 38, Japanese下大静脈塞栓を有する腎癌患者に対する術前分子標的治療薬投与の有用性に関する検討
- BACKGROUND: Nomograms have been developed for the prediction of progression-free survival (PFS) and liver toxicity in patients with advanced renal cell carcinoma (RCC) who are treated with pazopanib. The objectives of this study were to review clinical outcomes, to perform an external validation of these nomograms and to develop a new nomogram in Japanese patients. METHODS: A retrospective chart review of 150 Japanese patients with advanced RCC who received pazopanib at Kobe University Hospital and affiliated hospitals from March 2014 to June 2017 was performed. We evaluated the clinical efficacy and safety of pazopanib using logistic regression analysis to analyze the prognostic factors for overall survival (OS) and PFS. For nomogram validation, concordance index (C-index) and calibration were used. RESULTS: The median PFS and OS in this study was 13.1 and 37.4 months, respectively. Multivariate analyses identified prognostic factors for OS (number of metastasis, white blood cell (WBC) count and lactate dehydrogenase) and PFS (number of metastasis, WBC count). The C-index of nomograms for 12-month PFS was 0.598. The C-index of nomograms for liver toxicity was 0.558. A new Nomogram for predicting 12-month PFS for patients who received pazopanib was developed and performed internal validation. The C-index of the nomogram was 0.768. CONCLUSION: The clinical effect and safety of pazopanib reported in this study was similar to previous studies. This study suggests careful application of nomograms to Japanese patients treated with pazopanib. We have developed a new nomogram for predicting 12-month PFS with pazopanib therapy from Japanese patients.Jun. 2019, International journal of clinical oncology, 24(6) (6), 698 - 705, English, Domestic magazineScientific journal
- 日本老年泌尿器科学会, May 2019, 日本老年泌尿器科学会誌, 32(1) (1), 187 - 187, Japanese
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 141, Japanese淡明細胞型腎細胞癌に対するfirst-line Sunitinibの治療成績
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 146, Japanese神戸大学における進行性腎癌に対する2nd lineアキシチニブの治療成績
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 270, Japanese神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌7例の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 459, Japanese神戸大学における進行性腎癌に対するニボルマブの臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP2 - 097, Japaneseハイリスク前立腺癌に対するロボット根治的前立腺全摘除術の治療成績
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 069, Japanese転移性副腎腫瘍に対する腹腔鏡下副腎摘除術の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 185, Japanese腎癌下大静脈腫瘍塞栓を有する患者に対して術前分子標的薬投与を行った際の手術成績の比較検討
- 日本老年泌尿器科学会, Nov. 2018, 日本老年泌尿器科学会誌, 31, 115 - 115, Japanese
- Oct. 2018, INTERNATIONAL JOURNAL OF UROLOGY, 25, 367Interposition of novel nerve-regeneration conduit after non nerve-sparing radical prostatectomy: short-term results from a prospective trial[Refereed]
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P32 - 2, English進行腎癌に対するニボルマブの効果予測因子の検討
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P43 - 6, English去勢抵抗性前立腺癌患者におけるアビラテロン効果予測因子としての血清DHEAS値の検討
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P44 - 8, English当院における去勢抵抗性前立腺癌に対するカバジタキセルの治療経験
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P98 - 4, English下大静脈塞栓を有する腎癌患者に対する術前補助化学療法としてのパゾパニブの使用経験
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P98 - 6, English転移性腎細胞癌に対するパゾパニブの治療成績
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P98 - 7, Englishパゾパニブ使用した進行腎癌症例の無増悪生存、および肝障害ノモグラムの有用性の検討
- (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P100 - 3, English当院における切除不能腎癌に対するnivolumabの治療成績
- 泌尿器科紀要刊行会, May 2018, 泌尿器科紀要, 64(5) (5), 237 - 237, Japanese神戸大学における転移性腎癌に対するニボルマブの初期経験
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, OP - 184, Japanese神戸大学における転移性腎癌に対するニボルマブの初期経験
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, OP - 461, Japaneseパゾパニブを投与した進行腎癌症例における無増悪生存、および肝障害に対するノモグラムの有用性の検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, OP - 581, Japanese根治的膀胱全摘除術における非禁制型尿路変向術の術後腎機能に与える影響の検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, PP1 - 179, Japanese神戸大学病院における転移性腎癌に対する分子標的薬の治療成績についての臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, PP1 - 183, JapanesePresurgical therapyとしてTyrosine Kinase Inhibitors(TKIs)を使用した腎細胞癌症例の検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, PP2 - 011, JapanesePD-L1発現を低下させた腎癌細胞を接腫したマウスにおけるsunitinibの抗腫瘍効果についての検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2018, 日本泌尿器科学会総会, 106回, PP2 - 139, Japanese当院で施行したロボット支援根治的前立腺全摘除術におけるpT3症例の生物学的再発予測因子
- 日本老年泌尿器科学会, Mar. 2018, 日本老年泌尿器科学会誌, 30, 106 - 106, Japanese
- To investigate the efficacy and safety of first-line Pazopanib advanced or metastatic renal cell carcinoma (RCC): a single-institution study. (Patients and methods) We gathered 23 RCC patients treated between April 2014 and February 2018 in our institution and examined the treatments outcome and adverse events (AEs). (Results) Their risk criteria were categorized as follows: Favorable (n=2), Intermediate (n=12) and Poor (n=9) by International mRCC Database Consortion (IMDC). Median progression free survival (PFS) was 8.6 months and median overall survival (OS) was unreached. Best response (BR) of Pazopanib was partial response (PR): n=10, 50.0%, stable disease (SD): n=8, 40.0% and progression disease (PD): n=2, 10.0% (Three patients had no evaluable data,). AEs of Grade3 had liver dysfunction (n=3), thrombocytopenia (n=2), hand-foot syndrome (n=1), vomiting (n=1) and bowel bleeding (n=1). (Conclusion) The fist-line pazopanib demonstrated good clinical benefit with well-tolerance.2018, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 109(4) (4), 216 - 219, Japanese, Domestic magazineScientific journal
- (一社)日本泌尿器内視鏡学会, Nov. 2017, Japanese Journal of Endourology, 30(3) (3), 267 - 267, Japanese
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P9 - 4, Japaneseロボット支援腎部分切除術におけるRENAL nephrometry scoreと手術成績に関する検討
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P27 - 6, Japanese下大静脈塞栓を有する腎癌患者に対する術前補助化学療法としてのパゾパニブの使用経験
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P27 - 7, Japanese当院における進行性腎細胞癌に対するパゾパニブの治療成績
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P89 - 4, Japaneseロボット支援腹腔鏡下前立腺全摘除術における拡大リンパ節郭清の成績
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P96 - 6, Japanese根治的前立腺全摘除術Gleason Score 8-10症例の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, OP05 - 6, Japanese根治的前立腺全摘除術Gleason Score 8-10症例の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2017, 日本泌尿器科学会総会, 105回, PP52 - 09, Japanese当院および関連施設における去勢抵抗性前立腺癌に対するアビラテロンの治療成績についての検討
- [Clinical Outcome of Laparoscopic Partial Nephrectomy].The purpose of this study was to evaluate the safety and feasibility of laparoscopic partial nephrectomy with a small renal tumor. Between September 2004 and October 2014, 69 patients who underwent laparoscopic partial nephrectomy in Kansai Rosai Hospial were examined. The mean patient age was 60.3 years, and the mean tumor size was 24.5 mm. The mean estimated blood loss was 111 cc. The mean cold ischemic time was 59.7 minutes, and the mean warm ischemic time was 31.3 minutes. There were 5 complications : intraoperative ureteral injury, blood transfusion, postoperative perinephric hematoma, portsite bleeding, urinary fistula, respectively. All of the cases were cured with non-surgical treatment except ureteral injury which was repaired intraoperatively. The postoperative eGFR loss was 11%. At present, no patients have developed local recurrence or distant metastasis. The initial outcome of laparoscopic partial nephrectomy in our hospital was satisfactory in terms of safety, renal function and cancer control.Aug. 2015, Hinyokika kiyo. Acta urologica Japonica, 61(8) (8), 317 - 20, Japanese, Domestic magazineScientific journal
- 泌尿器科紀要刊行会, May 2014, 泌尿器科紀要, 60(5) (5), 255 - 255, Japanese副腎癌に対して手術を施行しネフローゼ症候群が改善した1例
- Oct. 2020, INTERNATIONAL JOURNAL OF UROLOGY, 27, 74 - 75, EnglishClinical outcome of EP therapy (VP16+CDDP)in 10 prostate cancer patients with neuroendocrine differentiationSummary international conference
- Apr. 2020, JOURNAL OF UROLOGY, 203, E239 - E240, EnglishPREDICTIVE EFFICACYOF SERUMSOLUBLE PD-L1ONPATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMABSummary international conference
- 2020, 西日本泌尿器科, 82当院における腎癌患者のニボルマブとイピリムマブ併用療法の治療成績
- Apr. 2019, JOURNAL OF UROLOGY, 201(4) (4), E344 - E345, EnglishNEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMASummary international conference
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 141, Japanese淡明細胞型腎細胞癌に対するfirst-line Sunitinibの治療成績
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP2 - 097, Japaneseハイリスク前立腺癌に対するロボット根治的前立腺全摘除術の治療成績
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 069, Japanese転移性副腎腫瘍に対する腹腔鏡下副腎摘除術の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP3 - 185, Japanese腎癌下大静脈腫瘍塞栓を有する患者に対して術前分子標的薬投与を行った際の手術成績の比較検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 146, Japanese神戸大学における進行性腎癌に対する2nd lineアキシチニブの治療成績
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 270, Japanese神経内分泌癌化をきたし、EP療法(VP16+CDDP)を施行した前立腺癌7例の臨床的検討
- (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 459, Japanese神戸大学における進行性腎癌に対するニボルマブの臨床的検討
- 西日本泌尿器科学会, 20 Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
- 西日本泌尿器科学会, 20 Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese神戸大学における転移性腎癌に対するニボルマブの成績
- 西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese神戸大学における転移性腎癌に対するニボルマブの成績
- 西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 188 - 188, Japanese転移性非淡明細胞型腎細胞癌に対する分子標的治療薬の成績
- (一社)日本泌尿器内視鏡学会, Nov. 2017, Japanese Journal of Endourology, 30(3) (3), 267 - 267, Japaneseロボット支援腹腔鏡下前立腺全摘術におけるpT3症例の生物学的再発予測因子
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P89 - 4, Japaneseロボット支援腹腔鏡下前立腺全摘除術における拡大リンパ節郭清の成績
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会(Web), 55th, ROMBUNNO.P66‐2 (WEB ONLY) - 2, Japanese当院における去勢抵抗性前立腺癌に対するカバジタキセルの治療成績
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P66 - 2, Japanese当院における去勢抵抗性前立腺癌に対するカバジタキセルの治療成績
- (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P96 - 6, Japanese根治的前立腺全摘除術Gleason Score 8-10症例の臨床的検討
■ Research Themes
- Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), 01 Apr. 2020 - 31 Mar. 2023Development of novel bioabsorbable metal alloy for urinary tract surgery
従来は生体に非吸収性のチタンが用いられてきた自動縫合器に応用するための新規可溶性合金を開発し、自動縫合器を用いた腸管利用新膀胱造設術に応用するために、まずは計算シミュレーションに基づく亜鉛合金の組成を検討し、モデル合金を試作した。 その後、試作材について、成形性や強度、溶解性を評価するこ とにより最適な合金の組成を選定した。続いて、この合金をステープル型に成形し、小型動物(ラット)の膀胱内に全身麻酔下に手術で埋植し、飼育後に膀胱を 摘出し、尿路内でのステープルの溶解性、強度を評価するとともに、合金の埋植が生体に及ぼす影響につき検討した。 引き続き、大型動物(ブタ)の膀胱内に全身麻酔下に手術で新規可溶性合金ステープルを埋植し、3カ月間飼育した後に安楽死させ、埋植部の組織結合性、縫合部周囲の炎症、結石形成性を評価すること により、尿路に使用した場合の安全性と有用性につき検討した。 - Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2017 - 31 Mar. 2020Genome analysis during recurrence of urothelial cancerAll exome analysis was performed on 4 cases, 4 samples at the first onset, and 5 samples at the time of recurrence (including 1 case relapse). The average depth of the specimen was 117 and 12046 SNVs were identified on average. The common SNVs in the first and recurrent cases were 10683 on average in 4 cases, and it is considered that they have the same origin from the phylogenetic tree analysis, but this analysis alone cannot conclude either seeding or multicentric development It was Many gene mutations reported in The Cancer Genome Atlas were also found. FAM8A1, HLA-DRB1, HLA-DRB5, HRNR, NBPF1, NBPF10, NBPF20, and PABPC3 were found as common mutated genes in recurrent cases.